Why the study?
Do fibrinolytic agents (urokinase and streptokinase) improve outcomes and have acceptable safety compared to traditional anticoagulants in patients with deep-vein thrombosis and pulmonary embolism?
Do fibrinolytic agents (urokinase and streptokinase) improve outcomes and have acceptable safety compared to traditional anticoagulants in patients with deep-vein thrombosis and pulmonary embolism?
An NIH consensus panel urges greater use of fibrinolytic agents (urokinase and streptokinase) over heparin for DVT and PE, citing superior long-term benefits and acceptable bleeding risks.
Answers are grounded in this paper and cite their sources.
Urges greater use of urokinase or streptokinase over heparin for DVT and PE; reinforces consensus favoring fibrinolysis in venous thromboembolism.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
John F. Elliott (1980) studied deep-vein thrombosis and pulmonary embolism. urokinase and streptokinase vs. traditional anticoagulants (heparin sodium) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: